UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 48

Sortiert nach

FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors

Clinical cancer research, 2019-07, Vol.25 (13), p.3753-3758

2019

Volltextzugriff (PDF)

FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors

Clinical cancer research, 2021-09, Vol.27 (17), p.4685-4689

2021

Volltextzugriff (PDF)

FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine-Refractory Differentiated Thyroid Cancer

Clinical cancer research, 2015-12, Vol.21 (23), p.5205-5208

2015

Volltextzugriff (PDF)

FDA Approval Summary: Ramucirumab for Gastric Cancer

Clinical cancer research, 2015-08, Vol.21 (15), p.3372-3376

2015

Volltextzugriff (PDF)

FDA Approval Summary: TAS-102

Clinical cancer research, 2017-06, Vol.23 (12), p.2924-2927

2017

Volltextzugriff (PDF)

FDA's Approval of the First Biosimilar to Bevacizumab

Clinical cancer research, 2018-09, Vol.24 (18), p.4365-4370

2018

Volltextzugriff (PDF)

FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma

Clinical cancer research, 2021-04, Vol.27 (7), p.1836-1841

2021

Volltextzugriff (PDF)

Tissue-Agnostic Drug Development: A New Path to Drug Approval

Cancer discovery, 2021-09, Vol.11 (9), p.2139-2144

2021

Volltextzugriff (PDF)

FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma

Clinical cancer research, 2021-09, Vol.27 (17), p.4680-4684

2021

Volltextzugriff (PDF)

FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation

Clinical cancer research, 2022-07, Vol.28 (13), p.2733-2737

2022

Volltextzugriff (PDF)

FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma

Clinical cancer research, 2024-01, Vol.30 (2), p.269

2024

Volltextzugriff (PDF)

FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2-Positive RAS Wild-Type Colorectal Cancer

Clinical cancer research, 2023-11, Vol.29 (21), p.4326

2023

Volltextzugriff (PDF)

FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement

Clinical cancer research, 2023-03, Vol.29 (5), p.838-842

2023

Volltextzugriff (PDF)

FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other Rearrangements

Clinical cancer research, 2023-10, Vol.29 (20), p.4027

2023

Volltextzugriff (PDF)

FDA Approval Summary: Nivolumab for the Adjuvant Treatment of Adults with Completely Resected Esophageal/Gastroesophageal Junction Cancer and Residual Pathologic Disease

Clinical cancer research, 2022-12, Vol.28 (24), p.5244-5248

2022

Volltextzugriff (PDF)

FDA's Approach to Regulating Biosimilars

Clinical cancer research, 2017-04, Vol.23 (8), p.1882-1885

2017

Volltextzugriff (PDF)

FDA Approval Summary: Ripretinib for Advanced Gastrointestinal Stromal Tumor

Clinical cancer research, 2023-06, Vol.29 (11), p.2020-2024

2023

Volltextzugriff (PDF)

Subgroup Analyses in Oncology Trials: Regulatory Considerations and Case Examples

Clinical cancer research, 2021-11, Vol.27 (21), p.5753-5756

2021

Volltextzugriff (PDF)

FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors

Clinical cancer research, 2023-09, Vol.29 (18), p.3573

2023

Volltextzugriff (PDF)

U.S. Food and Drug Administration Approval: Ofatumumab for the Treatment of Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine and Alemtuzumab

Clinical cancer research, 2010-09, Vol.16 (17), p.4331-4338

2010

Volltextzugriff (PDF)

Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development

Cancer discovery, 2023-12, Vol.13 (12), p.2515

2023

Volltextzugriff (PDF)

The FDA Oncology Center of Excellence Scientific Collaborative: Charting a Course for Applied Regulatory Science Research in Oncology

Clinical cancer research, 2021-10, Vol.27 (19), p.5161-5167

2021

Volltextzugriff (PDF)

Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration-Melanoma Research Alliance Public Workshop

Clinical cancer research, 2021-01, Vol.27 (2), p.394-401

2021

Volltextzugriff (PDF)

Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy

Current oncology reports, 2020-11, Vol.22 (11), p.116-116, Article 116

2020

Volltextzugriff (PDF)

Eribulin Mesylate for the Treatment of Patients with Refractory Metastatic Breast Cancer: Use of a Physician's Choice Control Arm in a Randomized Approval Trial

Clinical cancer research, 2012-03, Vol.18 (6), p.1496-1505

2012

Volltextzugriff (PDF)

1 – 25 von 48

Suche als RSS-Feed

Aktive Filter

KollektionElsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(44)
Mit Volltextzugriff
(41)

Publikationsform

Artikel
(47)
Buchkapitel
(1)

Sprache

Englisch
(48)
Japanisch
(7)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors

FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors

FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine-Refractory Differentiated Thyroid Cancer

FDA Approval Summary: Ramucirumab for Gastric Cancer

FDA Approval Summary: TAS-102

FDA's Approval of the First Biosimilar to Bevacizumab

FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma

Tissue-Agnostic Drug Development: A New Path to Drug Approval

FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma

FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation

FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma

FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2-Positive RAS Wild-Type Colorectal Cancer

FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement

FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other Rearrangements

FDA Approval Summary: Nivolumab for the Adjuvant Treatment of Adults with Completely Resected Esophageal/Gastroesophageal Junction Cancer and Residual Pathologic Disease

FDA's Approach to Regulating Biosimilars

FDA Approval Summary: Ripretinib for Advanced Gastrointestinal Stromal Tumor

Subgroup Analyses in Oncology Trials: Regulatory Considerations and Case Examples

FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors

U.S. Food and Drug Administration Approval: Ofatumumab for the Treatment of Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine and Alemtuzumab

Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development

The FDA Oncology Center of Excellence Scientific Collaborative: Charting a Course for Applied Regulatory Science Research in Oncology

Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration-Melanoma Research Alliance Public Workshop

Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy

Eribulin Mesylate for the Treatment of Patients with Refractory Metastatic Breast Cancer: Use of a Physician's Choice Control Arm in a Randomized Approval Trial

Aktive Filter

Suchergebnisse filtern